Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. Show more

Location: 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, 94404, United States | Website: https://www.geron.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

842.6M

52 Wk Range

$1.04 - $3.59

Previous Close

$1.32

Open

$1.33

Volume

5,655,230

Day Range

$1.30 - $1.36

Enterprise Value

584M

Cash

380.5M

Avg Qtr Burn

-33.23M

Insider Ownership

0.10%

Institutional Own.

81.00%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RYTELO™ (Imetelstat) (GRN163L) Details Myelodysplastic syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imetelstat (GRN163L) Details Myelofibrosis	Phase 3 Interim Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imetelstat (GRN163L) Details Myelodysplastic syndrome, Acute myeloid leukemia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imetelstat (GRN163L)+ ruxolitinib Details Myelofibrosis	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.